Know exactly how your molecule is doing across the NHS.
DoseTrend tracks prescribing and dispensing for the molecules you care about, in one dashboard, with a monthly briefing PDF attached. £1,500 a month per molecule, and yes, we just told you the price.
The market has expensive syndicated data at one end, and PDFs at the other.
If you make or market a molecule sold in England, you either pay six figures for syndicated data, or you scrape NHSBSA CSVs yourself on a Tuesday afternoon. Neither is a good use of your week.
DoseTrend sits between the two. Every open dataset the NHS publishes, cleaned, joined and charted for one molecule at a time. Priced so a product manager can sign it off without a procurement round.
One molecule. Every angle we can honestly show you.
-
A · Trend
Monthly items and spend from November 2020, primary and secondary care in one series where the codes allow.Indexed views, YoY deltas, seasonality flags. For about 30 molecules, the number of people treated too, because NHSBSA publishes it for mental health, dependency-forming and diabetes medicines.
-
B · Geography
Every ICB, every practice, ranked and mapped.36 Integrated Care Boards, 7,317 GP practices. Filter by strength, formulation, indication where inferrable.
-
C · Hospital
SCMD data joined to primary care, so the picture is one picture.The two datasets use different vocabularies. We do the mapping once so you don't have to argue about it in a meeting.
-
D · Briefing
A monthly PDF written by a human, sent on the first working day.Two pages. What moved, why we think it moved, and what to watch next month. No dashboards to log into if you don't want to.
-
E · Signals
What happened, dated, on the chart.A NICE decision, an MHRA alert, a supply notice, a price concession, a new supplier in dm+d, a recall in the US. Each one quotes its source, and a person checks it before you see it. An email the day it lands, or a Monday summary.
-
F · Prices and contracts
What trusts paid, and who holds the NHS contract.Hospital prices paid shown as a range, because an average hides how widely trusts' prices vary. Who won each NHS framework line in each buying group, generics and branded, with every award back to 2016 and each line's history.
-
G · Tender Desk
Bid NHS generics tenders from the same data.Import the tender schedule and every line arrives with its hospital usage by region, the price trusts paid, the current holder and what has happened to the line before. Included with Molecule and Portfolio.
Ask Claude or ChatGPT. Get DoseTrend's figures.
Connect DoseTrend to the AI assistant your team already uses and ask in plain English: which ICBs are growing, how two molecules compare, who holds a dm+d listing. Every answer comes back with its data month, its caveats and its NHS source. Free for the public figures with no account. Subscribers sign in and it reaches their own molecules, included in every plan.
Built on open data, published in public.
Sources: NHSBSA prescribing, hospital medicines, Drug Tariff, dm+d and patient statistics; DHSC hospital prices (eMIT); NHS England framework awards, workplan and ODS reference data; MHRA and NICE. Mostly under the Open Government Licence v3.0; every source and its licence is on the data page.
What we won't pretend to show you.
Open data has limits and we'd rather you knew them before you pay us. For most generics you cannot see manufacturer-level brand share, because the NHS doesn't publish it. (Who won a hospital framework line is not the same thing, and we never present it as share.) Nothing is real time: NHSBSA publishes each month about eight weeks after it ends. Some ICBs code the same drug three different ways and we have to make judgement calls. If you need what open data can't give you, you need a paid pharmaceutical data provider and their budget. If you need everything else, you need us.
One price. Written on the tin.
£1,500 a month per molecule. Unlimited users at your company. Annual pays twelve months for eleven. Portfolios from three molecules up.
Tell us the molecule.
A human reads every application, and about one in ten gets told this isn't for them before any money moves. The rest get their sign-in within 24 hours. It saves both of us a bad month.